Home
overview

Vaccines are hailed as one of the most important public health achievements of the 20th century, fundamentally changing how clinicians prevent and treat disease and substantially impacting public health (Poland, Murray & Bonilla-Guerrero, 2007).

At a time of increasing demand and market for vaccines, SMi are proud to hold their 4th Biannual Vaccines Summit, bringing together the key players of the vaccine industry to work towards saving and enhancing lives.
Discover the newest developments in the four main fields of the vaccine industry: HIV, Cancer, Pandemic Flu and Neglected and Paediatric Diseases, and find out what the key market leaders do to overcome challenges to work towards their goals.

Who should attend and why:

As a vaccine manufacturer, hearing about your competitor’s vaccine manufacturing capabilities and strategies will enable you to identify their strengths and weaknesses, allowing you to exploit your competitive advantage and respond to future market opportunities faster.
Putting you face to face with the key players of the vaccines manufacturing field and government delegates will allow you to build up relationships for your biotechnology company that could lead to successful partnerships and invaluable advice on corporate strategy, funding and investment into research and development.
Meeting the people behind vaccine technology will give you a deeper insight into the industry and will allow you to establish relationships between your government organisation that will lead to successful health campaigns to ensuring domestic and global health.
The exceptional networking possibilities for CROs at this event will give you the opportunity to present your research and development capabilities, allowing you to position your company most effectively in the corporate landscape.

Our exceptional speaker line-up includes:
  • Dr Juergen Zorn, Senior Medical Manager, Pharmacovigilance, Novartis Vaccines and Diagnostics GmbH & Co. KG
  • Dr Ashoni Arora, Wyeth
  • Dr Volker Brauer, Medical Manager, Development Pandemic Influenza Vaccines, Novartis Vaccines and Diagnostics GmbH & Co. KG
  • Dr Tony Colegate, Influenza Technical Affairs Manager, Novartis
  • Dr Anne Fiquet, Study Design & Evaluation Manager, Clinical Development, Sanofi Pasteur MSD

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

John Dong

John Dong, President & Chief Scientific Officer, GenPhar

9:10 PROGRESS IN HIV VACCINE DEVELOPMENT: POST STEP ERA

Juliana McElrath

Juliana McElrath, Director of Laboratories for HIV Vaccine Trial Network, Fred Hutchinson Cancer Research Center

  • Why did the Merck HIV Vaccine Fail?
  • What biological mechanisms may explain why enhancement of HIV infection potentially occurred in the vaccinated subgroup with previous Ad5 immunity?
  • Do T cell-based vaccines have a role in protecting against HIV infection or disease?  
  • What investigations are needed to move the field forward

9:50 HIV PROPHYLACTIC VACCINES ARE POINTLESS

Angus Dalgleish

Angus Dalgleish, Professor of Oncology, Onyvax

·                 Non-neutalising epitopes
·                 Targets to prevent disease
·                  Pitfalls of prophylactic vaccines

10:30 Morning Coffee

11:00 NOVEL LIPOSOMAL VACCINE FORMULATIONS

Andrew Bacon

Andrew Bacon, Principal Scientist, Lipoxen PLC

• Liposomal vaccines

• Versatile delivery systems for vaccine antigens

• Co-delivery protein and DNA vaccines

• ‘Virtual Conjugate’ polysaccharide vaccines in liposomes

• Oppurtunities for new vaccine products

11:40 "PROGRESS IN THE DEVELOPMENT OF A MENINGOCOCCAL SEROGROUP B VACCINE" - A SIGNIFICANT UNMET NEED

Ashoni Arora

Ashoni Arora, Vaccines Clinical Research, Wyeth-Lederle Vaccines & Paediatrics

12:20 Networking Lunch

13:50 CADVAX-BASED VACCINE PLATFORM FOR DEVELOPING SAFE AND EFFECTIVE VACCINES AGAINST LETHAL VIRAL INFECTIONS SUCH AS EBOLA

John Dong

John Dong, President & Chief Scientific Officer, GenPhar

·                 How a vaccine starts from a concept to a product
·                 Challenges that can be expected in the progress of vaccine development
·                 HPV to cervical cancer: the facts and statistics
·                 Mechanism of Cervarix’s function in immunizing against HPV

14:30 NEGLECTED DISEASES: NEW OPPORTUNITIES

Graham Clarke

Graham Clarke, Chief Executive Officer, ImmunoBiology Ltd

16:00 Chairman’s Closing Remarks

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

John Dong

John Dong, President & Chief Scientific Officer, GenPhar

9:10 TACKLING JAPANESE ENCEPHALITIS

Christoph Klade

Christoph Klade, Vice President, Technology Development & Clinical Immunology, InterCell A G

·                 The evolution of Japanese Encephalitis
·                 Addressing the need for Japanese Encephalitis vaccines
·                 Progress update on Intercell’s phase 3 vaccine candidate
·                 Japanese Encephalitis’s geographical spread and it’s impact on vaccine sales
·                 Strategies for ensuring that afflicted areas have access to the vaccine

9:50 REGULATORY & CLINICAL DESIGN ISSUES IN BIOSAFETY

Anne Fiquet

Anne Fiquet, Study Design and Evaluation Manager, Europe, Sanofi Pasteur MSD

  • Increased scrutiny
  • Impact on development plans
  • Design issues vs. feasibility
  • 10:30 Morning Coffee

    12:20 Networking Lunch

    13:50 DEVELOPMENT OF BAXTER'S PANDEMIC INFLUENZA VACCINE - PAST, PRESENT AND FUTURE

    Alexandra Loew-Basselli

    Alexandra Loew-Basselli, Director, Clinical Development, Baxter A G

    • Using the Vero cell platform for influenza vaccines

    • Immunogenicity and cross protection in animals

    • Clinical trial strategy and first data in humans - safety,

    • Immunogenicity and cross-reactivity

    • Boosting with homologous and heterologous strains

    • Licensure challenges and post-licensure commitments

    14:30 '90 YEARS OF QUARANTINE STUDIES WITH INFLUENZA 1918-2008'

    Anthony Gilbert

    Anthony Gilbert, Medical Director, Retroscreen Virology Limited

    • The truth about Influenza vaccine supply

    • Factors affecting the expansion of vaccine manufacturing

    • Meeting the needs of influenza vaccines: adjuvants, universal vaccines, needle-free vaccines

    • What Europe is doing about the impending H5N1 wave

    • What the US and Japan are doing about the impending H5N1 wave

    • The danger of H5N1 as portrayed by the media and the real impact of a population’s disease awareness

    16:00 Chairman’s Closing Remarks

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.